Life Science Connect Blog

  1. FDA News Roundup: Novo Nordisk, AstraZeneca, Merck, And More 4/10/2015

    What FDA decisions did you miss this week?

  2. FDA News Roundup: AstraZeneca, Teva, Amgen, And More 4/2/2015

    What regulatory decisions did you miss this week?

  3. FDA, EMA Drug Approval Stats: Are We Measuring Success The Wrong Way? 3/27/2015

    While approval stats spark declarations of excitement from each regulatory agency and make news headlines, the differences in approval times in particular aren’t necessarily a cause for celebration; rather, they illuminate something much more concerning about the state of global drug development.

  4. FDA News Roundup: Merck, Actavis, Vertex, And More 3/20/2015

    What FDA decisions did you miss this week?
     

  5. Paying Clinical Trial Participants: Best Or Worst Practice? 3/13/2015

    Last week in my blog about the wacky legends healthy clinical trial volunteers tell in the clinic, I was particularly struck by the risks patients were supposedly willing to take for a large stipend. The impact of payments in clinical trials has been a topic I’ve noticed circulating through the industry over the past few weeks — especially in the case of H.I.V. trials.

  6. FDA News Roundup: Bristol-Myers Squibb, Bayer, Astellas, And More 3/11/2015

    What FDA decisions have you missed in the last week?

  7. FDA News Roundup: Shire, Bristol-Myers Squibb, Alexion, And More 3/6/2015

    What FDA decisions did you miss this week?

  8. Do Your Participants Have These 5 Misconceptions About Clinical Trials? 3/6/2015

    As a creative writer, I was drawn to the title of a recent study published in the journal Sociology Of Health And Illness: “Stopped Hearts, Amputated Toes, And NASA: Contemporary Legends Among Healthy Volunteers In U.S. Phase 1 Clinical Trials.” (Trust me—the study certainly lives up to its name.)

  9. FDA News Roundup: Pfizer, Novartis, Sanofi, and More 3/2/2015

    What drug approvals have you missed recently?

  10. What Pharma Is Learning From Retail: Is Omni-Channel Key To Patient Centricity? 2/27/2015

    I recently interviewed Susan Romberg of Chiltern on the ways pharma can use the Internet of Things to its advantage in the quest for patient centricity. She identified social media and wearable devices as innovations that will shake up project planning and drug development in the future. But her response that had nothing to do with technology, but rather location, took me back to my days of writing for retail.